MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alzh ...

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap. In 2016, the Company filed a patent covering the treatment of various ...

Annovis Bio (NYSE:ANVS) stock closed up a staggering 76% today on promising new data from its Phase 3 clinical study of its Parkinson’s treatment, buntanetap. Early results show that its buntanetap is both safe and effective in treating patients with early Parkinson’s, helping them retain and improve both motor and non-motor activities and cognitive functions.According to the data, buntanetap showed statistically significant improvements in cognitive ability in the overall population of Parkinson’s patients ...

文章核心观点 - 公司的新药物buntanetap在治疗帕金森病(PD)方面取得了积极的临床试验结果 [5] - buntanetap在改善PD患者的认知功能、运动功能和非运动功能方面均显示出显著疗效 [7][10][14] - buntanetap在PD患者中表现出良好的安全性 [16] 根据相关目录分别进行总结 认知功能改善 - 在整个入组人群中,安慰剂组出现认知功能下降,而buntanetap治疗组(10mg和20mg)维持基线水平,表明该药物在阻止认知功能下降方面具有统计学显著作用 [7] - 在轻度痴呆患者(MMSE 20-26)中,安慰剂组认知功能下降速度更快,而20mg buntanetap组显示出显著的认知改善 [8][9] 运动和非运动功能改善 - 在PD确诊超过3年的患者中,20mg buntanetap显著改善了MDS-UPDRS Part II、Part III、Part II+III和总分 [12] - 在姿势不稳和步态障碍(PIGD)患者中,buntanetap也显示出了同样的MDS-UPDRS改善效果 [14][15] 安全性 - buntanetap在早期和晚期PD患者中保持了一致的安全性概况,与之前的阿尔茨海默病数据一致 [16]

MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3 ...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed ...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed ...

MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: July 2, 2024, 4:30pm ET.Register Today: ...

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), today announces that its recent Phase II/III Alzheimer’s study of its lead drug candidate, Buntanetap, showed statistically significant efficacy and safety in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. Int ...

MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap. Investor Call Details: Date and Time: June 11, 2024, 4:30pm ET.Register Today ...